Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection

Blood

Volumn 117, Issue 20, 2011, Pages 5332-5339

  Biffi, Alessandra ^a,b   Bartholomae, Cynthia C ^c   Cesana, Daniela ^a,b,d   Cartier, Natalie ^e   Aubourg, Patrik ^e   Ranzani, Marco ^a,b,d   Cesani, Martina ^a   Benedicenti, Fabrizio ^a,b   Plati, Tiziana ^a,b   Rubagotti, Enrico ^a,b   Merella, Stefania ^a,b   Capotondo, Alessia ^a,b,d   Sgualdino, Jacopo ^a,b,d   Zanetti, Gianluigi ^f   Von Kalle, Christof ^c   Schmidt, Manfred ^c   Naldini, Luigi ^a,b,d   Montini, Eugenio ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e INSERM   (France)

^f CENTER FOR ADVANCED STUDIES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ADRENOLEUKODYSTROPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; COMMON INSERTION SITE; CONTROLLED STUDY; GENE CLUSTER; GENE INSERTION; GENE TARGETING; GENE TRANSFER; GENOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR CELL; VIRAL GENE THERAPY;

EID: 79954733266     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-306761     Document Type: Article

References (50)

1. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410-2413. (Pubitemid 34734219)
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185-1193. (Pubitemid 34984579)
3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818-823.
4. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419. (Pubitemid 37296260)
5. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;4:401-409.
6. Deichmann A, Hacein-Bey-Abina S, Schmidt M, et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest. 2007;117(8):2225-2232. (Pubitemid 47219567)
7. Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest. 2007;117(8):2241-2249. (Pubitemid 47219569)
8. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006;108(8):2545-2553.
9. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17(11):1919-1928.
10. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119(4):964-975.
11. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24(6):687-696. (Pubitemid 43882120)
12. Naldini L. Medicine. A comeback for gene therapy. Science. 2009;326(5954):805-806.
13. Kool J, Berns A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer. 2009;9(6):389-399.
14. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32(Database issue): D523-D527. (Pubitemid 38081713)
15. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol. 2007;14(4):337-342. (Pubitemid 46842807)
16. Capotondo A, Cesani M, Pepe S, et al. Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. Hum Gene Ther. 2007;18(9):821-836. (Pubitemid 47502848)
17. Follenzi A, Naldini L. HIV-based vectors. Preparation and use. Methods Mol Med. 2002;69:259-274.
18. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458.
19. Folks T, Benn S, Rabson A, et al. Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A. 1985;82(13):4539-4543. (Pubitemid 15233156)
20. Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest. 2006;116(11):3070-3082. (Pubitemid 44684492)
21. Schmidt M, Schwarzwaelder K, Bartholomae C, et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods. 2007;4(12):1051-1057. (Pubitemid 350201778)
22. University of California Santa Cruz. BLAT genome browser. http://genome.ucsc.edu.
23. Abel U, Deichmann A, Bartholomae C, et al. Real-time definition of non-randomness in the distribution of genomic events. PLoS ONE. 2007;2(6): e570.
24. Kool J, Uren AG, Martins CP, et al. Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. Cancer Res. 2010;70(2):520-531.
25. Uren AG, Kool J, Matentzoglu K, et al. Largescale mutagenesis in p19 (ARF) - and p53-deficient mice identifies cancer genes and their collaborative networks. Cell. 2008;133(4):727-741. (Pubitemid 351637624)
26. Bokhoven M, Stephen SL, Knight S, et al. Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol. 2009;83(1):283-294.
27. Wu X, Luke BT, Burgess SM. Redefining the common insertion site. J Virol. 2006;344(2):292-295. (Pubitemid 43049617)
28. Wang GP, Berry CC, Malani N, et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood. 2010;115(22):4356-4366.
29. Dave UP, Akagi K, Tripathi R, et al. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet. 2009;5(5): e1000491.
30. Lewinski MK, Bisgrove D, Shinn P, et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol. 2005;79(11):6610-6619. (Pubitemid 40677292)
31. Carteau S, Hoffmann C, Bushman F. Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol. 1998;72(5):4005-4014. (Pubitemid 28188704)
32. Li L, Yoder K, Hansen MS, Olvera J, Miller MD, Bushman FD. Retroviral cDNA integration: stimulation by HMG I family proteins. J Virol. 2000;74(23):10965-10974. (Pubitemid 32223961)
33. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521-529. (Pubitemid 35232295)
34. Ciuffi A, Bushman FD. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 2006;22(7):388-395. (Pubitemid 44015973)
35. Lewinski MK, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2006;2(6): e60.
36. Marshall HM, Ronen K, Berry C, et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS ONE. 2007;2(12): e1340.
37. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007;17(8):1186-1194. (Pubitemid 47204862)
38. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS. 2009;23(12):1461-1471.
39. Bushman FD, Malani N, Fernandes J, et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 2009;5(5): e1000437.
40. Wang GP, Levine BL, Binder GK, et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther. 2009;17(5):844-850.
41. Vatakis DN, Kim S, Kim N, Chow SA, Zack JA. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol. 2009;83(12):6222-6233.
42. Felice B, Cattoglio C, Cittaro D, et al. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS ONE. 2009;4(2): e4571.
43. Albanese A, Arosio D, Terreni M, Cereseto A. HIV-1 pre-integration complexes selectively target decondensed chromatin in the nuclear periphery. PLoS ONE. 2008;3(6): e2413.
44. MacNeil A, Sankale JL, Meloni ST, Sarr AD, Mboup S, Kanki P. Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo. J Virol. 2006;80(15):7316-7321. (Pubitemid 44092554)
45. Iglewicz B, Hoaglin DC. How to Detect and Handle Outliers. Milwaukee, WI: ASQC Quality Press; 1993.
46. Barnett V, Lewis T. Outliers in Statistical Data. 3rd ed. Chichester, NY: Wiley; 1994.
47. Biasco L, Ambrosi A, Pellin D, et al. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Medicine. 2011;3(2):89-101.
48. Boztug K, Schmidt M, Schwarzer A, et al. Stemcell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363(20):1918-1927.
49. de Ridder J, Uren A, Kool J, Reinders M, Wessels L. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol. 2006;2(12): e166.
50. Rad R, Rad L, Wang W, et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science. 2010;330(6007):1104-1107.